Helia Azodian Ghajar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Helia Azodian Ghajar has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Akram Mirzaei
Urology Research Center Tehran University of Medical Sciences Tehran Iran
2 shared publications - Rahil Mashhadi
Urology Research Center, Tehran University of Medical Sciences, Tehran, Iran, tums.ac.ir
2 shared publications - Seyed Mohammad Kazem Aghamir
Urology Research Center, Tehran University of Medical Sciences, Tehran, Iran
2 shared publications - AhmadReza Rezaeian
Urology Research Center, Tehran University of Medical Sciences, Tehran, Iran, tums.ac.ir
1 shared publication - Ali Tavoosian
Urology Research Center, Tehran University of Medical Sciences, Tehran, Iran, tums.ac.ir
1 shared publication - Fatemeh Khatami
Affiliation Urology Research Center, Tehran University of Medical Sciences, Tehran, Iran
1 shared publication
Latest Publications
- Open Access
- 1 January 2026
- Published by Wiley in Prostate Cancer
- Vol. 2026 (1) , 9093252
Metformin and Flutamide Combination Therapy’s Efficacy and Safety in Prostate Cancer Cell Lines
Background: Considering the hepatotoxicity and other side effects associated with flutamide as a first‐line treatment for prostate cancer (PCa), this study aimed to evaluate metformin as a potential anticancer agent to reduce the required dose of flutamide and thereby minimize its adverse effects. Method: We assessed the influence of metformin, flutamide, and metformin–flutamide combination therapy on LNCaP, DU145, and PC3 cell lines, which represent human PCa. The tests include wound‐healing assay, colony formation assay (CFA), analysis of apoptosis (programmed cell death) and cell cycle by flow cytometry, gene expression at the mRNA level by real‐time PCR ( BAX/BCL2 , E-cadherin , Snail , HIF1α , VEGFC , and KLK3 genes), and assessment of the treatments’ hepatotoxicity potential via measuring AST and ALT values. Result: To determine the IC50 (half‐maximal inhibitory concentration) values, cell lines were treated with different concentrations of the drugs. The IC50 values for metformin (800 μM) in the three cell lines and for flutamide (12 μM for PC3 and 10 μM for LNCaP/DU145), as determined by MTT assay, were confirmed by flow cytometry, indicating significant cell cycle arrest at the G0/G1 phase. The combination of metformin and flutamide significantly increased the BAX/BCL2 mRNA ratio in all three cell lines ( p < 0.0001) and downregulated the expression of KLK3 ( p < 0.01), HIF1α ( p < 0.01), VEGFC ( p < 0.001), and EMT pathway genes in PC3 and LNCaP ( p < 0.01). Liver injury assessment reported a reduction in flutamide’s hepatotoxicity in combination with metformin. Conclusion: Metformin in combination with flutamide reduced its dose and increased the sensitivity of PCa cells to treatment. Additionally, it mitigated the hepatotoxic effects of flutamide. Therefore, this combination may represent a new treatment strategy for PCa.
- 1 January 2026
- Published by Wiley in Prostate Cancer
- Vol. 2026 (1) , 9093252
Open AccessMetformin and Flutamide Combination Therapy’s Efficacy and Safety in Prostate Cancer Cell Lines
Background: Considering the hepatotoxicity and other side effects associated with flutamide as a first‐line treatment for prostate cancer (PCa), this study aimed to evaluate metformin as a potential anticancer agent to reduce the required dose of flutamide and thereby minimize its adverse effects. Method: We assessed the influence of metformin, flutamide, and metformin–flutamide combination therapy on LNCaP, DU145, and PC3 cell lines, which represent human PCa. The tests include wound‐healing assay, colony formation assay (CFA), analysis of apoptosis (programmed cell death) and cell cycle by flow cytometry, gene expression at the mRNA level by real‐time PCR ( BAX/BCL2 , E-cadherin , Snail , HIF1α , VEGFC , and KLK3 genes), and assessment of the treatments’ hepatotoxicity potential via measuring AST and ALT values. Result: To determine the IC50 (half‐maximal inhibitory concentration) values, cell lines were treated with different concentrations of the drugs. The IC50 values for metformin (800 μM) in the three cell lines and for flutamide (12 μM for PC3 and 10 μM for LNCaP/DU145), as determined by MTT assay, were confirmed by flow cytometry, indicating significant cell cycle arrest at the G0/G1 phase. The combination of metformin and flutamide significantly increased the BAX/BCL2 mRNA ratio in all three cell lines ( p < 0.0001) and downregulated the expression of KLK3 ( p < 0.01), HIF1α ( p < 0.01), VEGFC ( p < 0.001), and EMT pathway genes in PC3 and LNCaP ( p < 0.01). Liver injury assessment reported a reduction in flutamide’s hepatotoxicity in combination with metformin. Conclusion: Metformin in combination with flutamide reduced its dose and increased the sensitivity of PCa cells to treatment. Additionally, it mitigated the hepatotoxic effects of flutamide. Therefore, this combination may represent a new treatment strategy for PCa.
- 27 August 2024
- Published by Wiley in The FASEB Journal
- Vol. 38 (16) , e70004
Decellularized amniotic membrane hydrogel promotes mesenchymal stem cell differentiation into smooth muscle cells
Previous studies showed that the bladder extracellular matrix (B‐ECM) could increase the differentiation efficiency of mesenchymal cells into smooth muscle cells (SMC). This study investigates the potential of human amniotic membrane‐derived hydrogel (HAM‐hydrogel) as an alternative to xenogeneic B‐ECM for the myogenic differentiation of the rabbit adipose tissue‐derived MSC (AD‐MSC). Decellularized human amniotic membrane (HAM) and sheep urinary bladder (SUB) were utilized to create pre‐gel solutions for hydrogel formation. Rabbit AD‐MSCs were cultured on SUB‐hydrogel or HAM‐hydrogel‐coated plates supplemented with differentiation media containing myogenic growth factors (PDGF‐BB and TGF‐β1). An uncoated plate served as the control. After 2 weeks, real‐time qPCR, immunocytochemistry, flow cytometry, and western blot were employed to assess the expression of SMC‐specific markers (MHC and α‐SMA) at both protein and mRNA levels. Our decellularization protocol efficiently removed cell nuclei from the bladder and amniotic tissues, preserving key ECM components (collagen, mucopolysaccharides, and elastin) within the hydrogels. Compared to the control, the hydrogel‐coated groups exhibited significantly upregulated expression of SMC markers ( p ≤ .05). These findings suggest HAM‐hydrogel as a promising xenogeneic‐free alternative for bladder tissue engineering, potentially overcoming limitations associated with ethical concerns and contamination risks of xenogeneic materials.
- 27 August 2024
- Published by Wiley in The FASEB Journal
- Vol. 38 (16) , e70004
Decellularized amniotic membrane hydrogel promotes mesenchymal stem cell differentiation into smooth muscle cells
Previous studies showed that the bladder extracellular matrix (B‐ECM) could increase the differentiation efficiency of mesenchymal cells into smooth muscle cells (SMC). This study investigates the potential of human amniotic membrane‐derived hydrogel (HAM‐hydrogel) as an alternative to xenogeneic B‐ECM for the myogenic differentiation of the rabbit adipose tissue‐derived MSC (AD‐MSC). Decellularized human amniotic membrane (HAM) and sheep urinary bladder (SUB) were utilized to create pre‐gel solutions for hydrogel formation. Rabbit AD‐MSCs were cultured on SUB‐hydrogel or HAM‐hydrogel‐coated plates supplemented with differentiation media containing myogenic growth factors (PDGF‐BB and TGF‐β1). An uncoated plate served as the control. After 2 weeks, real‐time qPCR, immunocytochemistry, flow cytometry, and western blot were employed to assess the expression of SMC‐specific markers (MHC and α‐SMA) at both protein and mRNA levels. Our decellularization protocol efficiently removed cell nuclei from the bladder and amniotic tissues, preserving key ECM components (collagen, mucopolysaccharides, and elastin) within the hydrogels. Compared to the control, the hydrogel‐coated groups exhibited significantly upregulated expression of SMC markers ( p ≤ .05). These findings suggest HAM‐hydrogel as a promising xenogeneic‐free alternative for bladder tissue engineering, potentially overcoming limitations associated with ethical concerns and contamination risks of xenogeneic materials.